Humanwell Healthcare (Group) Co.,Ltd. (SHA:600079)

Market Cap	33.92B
Revenue (ttm)	24.18B
Net Income (ttm)	1.43B
Shares Out	1.63B
EPS (ttm)	0.87
PE Ratio	23.78
Forward PE	15.86
Dividend	0.47 (2.26%)
Ex-Dividend Date	Aug 19, 2025

Volume	15,984,754
Average Volume	21,621,910
Open	20.72
Previous Close	20.82
Day's Range	20.66 - 20.94
52-Week Range	19.37 - 25.90
Beta	0.47
RSI	48.13
Earnings Date	Oct 30, 2025

About SHA:600079

Humanwell Healthcare (Group) Co.,Ltd. researches, develops, produces, and sells pharmaceutical products in China and internationally. The company offers sufentanil citrate injection, an analgesic drug for combined anesthesia; remifentanil hydrochloride injection for induction of general anesthesia and maintenance of analgesia during general anesthesia; hydromorphone hydrochloride injection for patients who require opioid analgesia; nabuphine hydrochloride injection for use as an analgesic for anesthesia induction; alfentanil hydrochloride injec...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• Founded: 1988
• Employees: 17,650
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600079

Financial Performance

In 2024, SHA:600079's revenue was 25.44 billion, an increase of 3.71% compared to the previous year's 24.52 billion. Earnings were 1.33 billion, a decrease of -37.70%.